Uploaded byNicholas Weston Lawyers
Nw biotech fundamentals day 2 session 5 summary and wrap up
The biotech boot camp session highlighted trends in medical devices, diagnostics, industrial applications, life sciences, and agriculture, emphasizing a shift towards outcome-focused patient care and renewable bio-processes. The document noted the rapid maturation of the biotechnology sector, with increasing initial public offerings (IPOs) and a focus on innovative therapies. Additionally, it provided resources for further information on biotechnology regulations and industry developments.
More Related Content
Similar to Nw biotech fundamentals day 2 session 5 summary and wrap up
Nw biotech fundamentals day 2 session 5 summary and wrap up
- 1. Biotech Boot Camp Session5 – Summary and wrap-up Presenter: Nick Weston Melbourne, Brisbane, Sydney 28 May – 18 June, 2014
- 2. • Summary • Wrap-up 2 Session5 Overview Summary and wrap-up
- 3. • Summary • Wrap-up 3 Session5 Overview Summary and wrap-up
- 4. • Medical devicesand diagnostics • Industrial applications and clean-tech • Life sciences • Aquaculture and agriculture Biotechnology 4 Summary
- 5. • Medical devicesand diagnostics • Industrial applications and clean-tech • Life sciences • Aquaculture and agriculture Biotechnology 5 Summary
- 6. • A payer-drivenfocus on outcomes is driving device developers away from a focus on services delivered to an emphasis on achieving measurable results in patient health during entire episodes of care • A move to simple inexpensive consumer technologies that allow bypass of expensive and complex health information systems and can be a tool for improving care once patients are discharged from hospital Biotechnology 6 Medical devices and diagnostics
- 7. • Medical devicesand diagnostics • Industrial applications and clean-tech • Life sciences • Aquaculture and agriculture Biotechnology 7 Summary
- 8. • A shiftfrom petroleum-based economy combined with the exhaustion and soaring price of petroleum has resulted in an increased consumer awareness in the environmental impact of global warming (greenhouse gas, CO2 emission and pollution) • A move towards the development of renewable source- based bio-process and the replacement of chemical processes with bio-based ones Biotechnology 8 Industrial applications and cleantech
- 9. • Medical devicesand diagnostics • Industrial applications and clean-tech • Life sciences • Aquaculture and agriculture Biotechnology 9 Summary
- 10. • Next-generation sequencingand use of big-data analytics will increasingly be considered in diagnoses and treatment decisions • Immunotherapies, gene therapies, stem cell therapies and systems biology approaches are leading the charge into the genomics era Biotechnology 10 Life sciences
- 11. • Medical devicesand diagnostics • Industrial applications and clean-tech • Life sciences • Aquaculture and agriculture Biotechnology 11 Summary
- 12. • A moveaway from traditional practice of cultivating the soil, producing crops, and raising livestock, agriculture is employing GM techniques to enhance traits of plants and animals and increase the yield and productivity of crops whilst protecting the environment from harm • Agriculture and aquaculture are embracing biotechnology advances and allowing further development of biotechnological applications for use in medicines, diagnostics and life sciences Biotechnology 12 Agriculture and aquaculture
- 13. • Summary • Wrap-up 13 Session5 Overview Summary and wrap-up
- 14. Biotechnology 14 Wrap-up – IPOsin 2013 by market segment Source: Burrill Transforming Healthcare Report 2014 • 2013 best year fro biotech since 2000 • Globally, 65 IPOs completed • 7.5 billion raised • In U.S. 52 companies raised 7 billion on IPO (cf. 2012 where 16 companies raised 1.1B)
- 15. Biotechnology 15 Wrap-up – companiesare going public earlier Source: Burrill Transforming Healthcare Report 2014 Examples: • Epizyme (epigenetics) $88.7M • Bluebird Bio (gene therapy) $101M • Stemline Therapeutics (oncology stem cell) $38M • OncoMed Pharmaceuticals (oncology stem cell) $93.8M
- 16. Biotechnology 16 Wrap-up – itis not just human therapeutics doing well *Source: Burrill Transforming Healthcare Report 2014 Examples: • January 2013 – Zoetis, an animal health company (carved out of drug maker Pfizer Inc.) raised about US$2.2 billion in an IPO • May 2013 - Kamada, the maker of an inhalation device to treat the rare disease alpha-1 antitrypsin deficiency, raised $59.9 million in a Nasdaq IPO* • June 2013 - Aratana Therapeutics, an animal health company raised $57.5 million in a Nasdaq IPO • November 2013 - Evogene, an ag-biotech focussed on developing improved crop traits, raised $84.8 million in a NYSE IPO*
- 17. Biotechnology 17 Wrap-up – M&Ain 2013 by market segment (U.S.) Source: Burrill Transforming Healthcare Report 2014
- 18. Biotechnology 18 Wrap-up – Performanceof top Australian companies in 2013 Source: Burrill Transforming Healthcare Report 2014
- 19. Biotechnology is arapidly maturing and global sector Where once it was dependent on passing muster with regulators, its success is increasingly tied to payers Deal-making remains highly active Biotech companies have become subsumed into the broader economy (energy markets, food security, healthcare ecosystems) that they must understand to do well Biotechnology 19 Wrap-up
- 20. Biotechnology 20 Further resources • http://www.ich.org/products/guidelines.html(these guidelines are frequently referenced during the day development process, and cover the manufacturing, nonclinical and clinical requirements; use only some of parts of them depending on product) • www.tga.gov.au (regulatory, Australia) • www.fda.gov (regulatory, USA) • www.fda.gov/MedicalDevices/ (medical devices regulatory, USA) • www.ema.europa.eu/ema/ (regulatory, Europe) • www.ausbiotech.org (Australia’s biotechnology industry association)
- 21. Biotechnology 21 Further resources • www.ncbi.nlm.nih.gov/(access to biomedical and genomic information at the U.S. National Center for Biotechnology Information) • www.ncbi.nlm.nih.gov/pubmed (subscription only publication database for biomedical literature) • www.australian-aquacultureportal.com/ (portal to Australian aquaculture news and resources) • www.nal.usda.gov/ (US Department of Agriculture’s National Agricultural Library, the most comprehensive ag. resource) • www.crops.org (website of the Crops Science Society of America, news, publications, insights) • www.ars.usda.gov/main/main.htm (US Gov. Agriculture Research Service)
- 22. Biotechnology 22 Further resources • www.biomelbourne.org/vicbioportal(lists Victorian companies providing services to the sector) • www.stemcellsaustralia.edu.au/ (resources on stem cell technology) • www.innovation.gov.au/industry/biotechnology/ (biotech related resources and links) • www.nhmrc.gov.au/ (Australia’s National Health and Medical Research Council) • www.biotechnologyonline.gov.au/ (Basic resource covering Australian biotech sector and technologies)
- 23. Biotechnology 23 Further resources • www.ipaustralia.gov.au/(search engines for patents, designs and trade mark registrations in Australia) • www.wipo.int/portal/en/index.html (search engine for patents, designs and trade mark registrations internationally) • www.fiercebiotechresearch.com/ www.fiercebiotechresearch.com/ www.fiercebiotech.com/ www.fiercediagnostics.com/ www.fiercemedicaldevices.com/ (biotech sectoral news and insights) • www.buildingbiotechnology.com/ (starting, building and operating a biotechnology business) • www.fao.org/biotech/biotech-glossary/en/ (glossary of biotechnology terms)
- 24. Nick Weston T: +613 8616 0379 mail@nicholasweston.com Viktoriia Hristova T: +61 3 8616 0380 viktoriia@nicholasweston.com www.nicholasweston.com Wrap-up 24 THANK YOU